A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT ID: NCT01303796

Last Updated: 2022-06-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

482 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-01

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase 3 study assesses two drug regimens as the initial treatment of patients who are at least 70 years of age and have newly diagnosed acute myeloid leukemia (AML) for whom the doctor does not recommend the use of standard intensive treatment or the patient has decided not to receive standard intensive treatment after being fully informed about its benefits and risks by his/her doctor. The two drug regimens are sapacitabine administered in alternating cycles with decitabine or decitabine alone. The purpose of the study is to learn which drug regimen is more likely to keep AML in check as long as possible.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter, randomized, Phase 3 study ("SEAMLESS") comparing two drug regimens (arms) as the front-line treatment of elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy. In Arm A, sapacitabine is administered in alternating cycles with decitabine, and in Arm C decitabine is administered alone. The primary efficacy endpoint is overall survival. The study is designed to demonstrate an improvement in overall survival of Arm A versus Arm C.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sapacitabine-decitabine alternating

Arm A sapacitabine administered in alternating cycles with decitabine

Group Type EXPERIMENTAL

Sapacitabine

Intervention Type DRUG

Oral sapacitabine capsules

Decitabine

Intervention Type DRUG

Decitabine intravenous

Decitabine

Arm C Decitabine

Group Type ACTIVE_COMPARATOR

Decitabine

Intervention Type DRUG

Decitabine intravenous

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sapacitabine

Oral sapacitabine capsules

Intervention Type DRUG

Decitabine

Decitabine intravenous

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CYC682 Decitabine intravenous

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly diagnosed AML based on WHO (World Health Organization) classification
* Age 70 years or older for whom the treatment of choice is low-intensity therapy by investigator assessment or who has refused intensive induction therapy recommended by investigator
* ECOG (Eastern Cooperative Oncology Group) performance status 0-2
* Adequate renal function
* Adequate liver function
* Able to swallow capsules
* Agree to practice effective contraception
* Ability to understand and willingness to sign the informed consent form

Exclusion Criteria

* AML is of the sub-type of acute promyelocytic leukemia or extramedullary myeloid tumor without bone marrow involvement
* Having received any systemic anti-cancer therapy for AML or received treatment with hypomethylating agents or cytotoxic chemotherapy for preceding myelodysplastic syndrome (MDS) or myeloproliferative disease (MPD)
* Known or suspected central nervous system (CNS) involvement by leukemia
* Uncontrolled intercurrent illness
* Known hypersensitivity to decitabine
* Known to be HIV-positive
Minimum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cyclacel Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hagop M Kantarjian, M.D.

Role: STUDY_CHAIR

M.D. Anderson Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama Comprehensive Cancer Center

Birmingham, Alabama, United States

Site Status

Scripps Cancer Center

La Jolla, California, United States

Site Status

UCLA Ronald Reagan Medical Center

Los Angeles, California, United States

Site Status

Norwalk Hospital

Norwalk, Connecticut, United States

Site Status

Shands Cancer Hospital at University of Florida

Gainesville, Florida, United States

Site Status

Cleveland Clinic Florida

Weston, Florida, United States

Site Status

Winship Cancer Institute, Emory University

Atlanta, Georgia, United States

Site Status

Blood and Marrow Transplant Group of Georgia

Atlanta, Georgia, United States

Site Status

Northwestern Memorial Hospital

Chicago, Illinois, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

The University of Chicago Medical Center

Chicago, Illinois, United States

Site Status

St. Francis Medical Group Oncology and Hematology Specialists

Indianapolis, Indiana, United States

Site Status

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

Site Status

University of Maryland Greenbaum Cancer Center

Baltimore, Maryland, United States

Site Status

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status

Henry Ford Health System

Detroit, Michigan, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

Saint Luke's Cancer Institute

Kansas City, Missouri, United States

Site Status

St. Louis University Cancer Center

St Louis, Missouri, United States

Site Status

University of Nebraska Medical Center

Omaha, Nebraska, United States

Site Status

Dartmouth - Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

John Theurer Cancer Center at the Hackensack University Medical Center

Hackensack, New Jersey, United States

Site Status

Westchester Hematology Oncology Group, PC

Hawthorne, New York, United States

Site Status

Beth Israel Medical Center

New York, New York, United States

Site Status

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Site Status

Stony Brook University Medical Center

Stony Brook, New York, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

Gabrail Cancer Center Research

Canton, Ohio, United States

Site Status

University of Cincinnati

Cincinnati, Ohio, United States

Site Status

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status

Penn State Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Saint Francis Hospital

Greenville, South Carolina, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

Baylor University Medical Center

Dallas, Texas, United States

Site Status

MD Anderson Cancer Center

Houston, Texas, United States

Site Status

Joe Arrington Cancer Research and Treatment Center

Lubbock, Texas, United States

Site Status

Huntsman Cancer Institute at the University of Utah

Salt Lake City, Utah, United States

Site Status

The Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Site Status

Medizinische Universitaetsklinik

Innsbruck, , Austria

Site Status

Elisabethinen Krankenhaus

Linz, , Austria

Site Status

Krankenhaus der Barmherzigen Schwestern

Linz, , Austria

Site Status

Univ. Klinik fur Innere Medizin III LKH

Salzburg, , Austria

Site Status

AKH Wien

Vienna, , Austria

Site Status

Hanusch Krankenhaus

Vienna, , Austria

Site Status

Klinikum Wels-Grieskirchen GmbH

Wels, , Austria

Site Status

Ziekenhuis Netwerk Antwerpen Stuivenberg

Antwerp, , Belgium

Site Status

AZ Sint-Jan Brugge-Oostende

Bruges, , Belgium

Site Status

Universite Catholique de Louvain

Brussels, , Belgium

Site Status

Centre Hospitalier De Jolimont-Lobbes

La Louvière, , Belgium

Site Status

Cliniques Universitaires UCL de Mont-Godinne

Yvoir, , Belgium

Site Status

CHU d'Amiens Hopital Sud

Amiens, , France

Site Status

Centre Hospitalier de la Cote Basque

Bayonne, , France

Site Status

CHU de Lyon - Hopital Edouard Herriot

Lyon, , France

Site Status

Institut Paoli Calmettes

Marseille, , France

Site Status

CHRU De Montpellier Hopital St. Eloi

Montpellier, , France

Site Status

Centre Hospitalier De Mulhouse

Mulhouse, , France

Site Status

Hopital St Louis Universite Paris 7

Paris, , France

Site Status

Centre Hospitalier de Perigueux

Périgueux, , France

Site Status

Centre Hospitalier d'Annecy

Pringy, , France

Site Status

Centre Hospitalier de Saint-Brieuc Yves Ie Foll

Saint-Brieuc, , France

Site Status

CHU de Strasbourg - Hopital Civil

Strasbourg, , France

Site Status

Strasbourg Oncologie Liberale

Strasbourg, , France

Site Status

CHU de Tours Hopital Bretonneau

Tours, , France

Site Status

Universitaetsklinikum Charite Berlin, Campus Benjamin Franklin

Berlin, , Germany

Site Status

Universitaetsklinikum Carl-Gustav-Carus Dresden

Dresden, , Germany

Site Status

St. Johannes Hospital

Duisburg, , Germany

Site Status

Klinikum Frankfurt Hoechst

Frankfurt, , Germany

Site Status

Asklepios Klinik Altona

Hamburg, , Germany

Site Status

Medizinische Hochschule Hannover

Hanover, , Germany

Site Status

SLK Kliniken Heilbronn

Heilbronn, , Germany

Site Status

Klinikum St. Georg

Leipzig, , Germany

Site Status

Johannes Wesling Klinikum

Minden, , Germany

Site Status

TU Muenchen

München, , Germany

Site Status

Universitaetsklinikum Muenster

Münster, , Germany

Site Status

University of Debrecen

Debrecen, , Hungary

Site Status

Petz Aladar Megyei Oktato Korhaz

Győr, , Hungary

Site Status

Kaposi Mor Oktato Korhaz

Kaposvár, , Hungary

Site Status

AOU Ospedali Riuniti Umberto I

Ancona, , Italy

Site Status

AO Ospedali Riuniti di Bergamo

Bergamo, , Italy

Site Status

Universita di Bologna Ist Ematologia Oncologia Medica Seragnoli

Bologna, , Italy

Site Status

AO Spedali Civili di Brescia

Brescia, , Italy

Site Status

Universita Cattolica del Sacro Cuore

Campobasso, , Italy

Site Status

AOU Careggi

Florence, , Italy

Site Status

AOU San Martino IST

Genova, , Italy

Site Status

PO Vito Fazzi

Lecce, , Italy

Site Status

Ospedale San Raffaele

Milan, , Italy

Site Status

AORN Antonio Cardarelli

Napoli, , Italy

Site Status

Uni. Napoli Ospedale Federico lI

Napoli, , Italy

Site Status

AOU Maggiore della Carità di Novara

Novara, , Italy

Site Status

AOOR Villa Sofia Cervello di Palermo

Palermo, , Italy

Site Status

Policlinico San Matteo Di Pavia

Pavia, , Italy

Site Status

AOU San Luigi Gonzaga

Torino, , Italy

Site Status

Akademickie Centrum Kliniczne Szpital Akademii Medycznej w Gdansku

Gdansk, , Poland

Site Status

Wojewodzki Szpital Specjalistyczny

Legnica, , Poland

Site Status

Wojewódzki Szpital Specjalistyczny w Legnicy

Legnica, , Poland

Site Status

University of Lodz N. Copernicus Memorial Hospital

Lodz, , Poland

Site Status

IHT Instytut Hematologii I Transfuzjologii w Warszawie

Warsaw, , Poland

Site Status

Samodzielny Publiczny Szpital Kliniczny Nr 1 w Wroclawiu

Wroclaw, , Poland

Site Status

Hospital Universitari Germans Trias i Pujol ICO Badalona

Badalona, , Spain

Site Status

Hospital Clinic de Barcelona

Barcelona, , Spain

Site Status

Hospital De La Santa Creu Sant Pau

Barcelona, , Spain

Site Status

Hospital Universitario Vall d'Hebron

Barcelona, , Spain

Site Status

Hospital Universitario Ramon y Cajal

Madrid, , Spain

Site Status

MD Anderson Cancer Center

Madrid, , Spain

Site Status

Hospital Son Llatzer

Palma de Mallorca, , Spain

Site Status

Hospital Universitari Son Espases

Palma de Mallorca, , Spain

Site Status

Clínica Universidad de Navarra

Pamplona, , Spain

Site Status

Complejo Hospitalario de Navarra

Pamplona, , Spain

Site Status

Hospital Clinico Universitario de Salamanca

Salamanca, , Spain

Site Status

Hospital Universitario de Canarias

San Cristóbal de La Laguna, , Spain

Site Status

Hospital Clinico Universitario

Santiago de Compostela, , Spain

Site Status

Hospital Universitario Virgen del Rocio

Seville, , Spain

Site Status

Hospital Universitari "La Fe"

Valencia, , Spain

Site Status

Sunderby Hospital

Luleå, , Sweden

Site Status

Skåne Universitetssjukhus Univ Hospital Lund

Lund, , Sweden

Site Status

Inselspital Bern

Bern, , Switzerland

Site Status

Kings College Hospital and Guys and St Thomas' Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Austria Belgium France Germany Hungary Italy Poland Spain Sweden Switzerland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Kantarjian HM, Begna KH, Altman JK, Goldberg SL, Sekeres MA, Strickland SA, Arellano ML, Claxton DF, Baer MR, Gautier M, Berman E, Seiter K, Solomon SR, Schiller GJ, Luger SM, Butrym A, Gaidano G, Thomas XG, Montesinos P, Rizzieri DA, Quick DP, Venugopal P, Gaur R, Maness LJ, Kadia TM, Ravandi F, Buyse ME, Chiao JH. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer. 2021 Dec 1;127(23):4421-4431. doi: 10.1002/cncr.33828. Epub 2021 Aug 23.

Reference Type RESULT
PMID: 34424530 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://pubmed.ncbi.nlm.nih.gov/34424530/

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CYC682-12

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.